Efthymios N. Deliargyris

Showing 1-4 of 4 articles

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials

Vaduganathan M, Harrington R, Stone G, Steg P, Gibson M, Hamm C, Price M, Lopes R, Leonardi S, Deliargyris E, Prats J, Mahaffey K, White H, Bhatt D

February 2, 2018 | 10.4244/EIJ-D-17-00723

Coronary interventions

Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study

van Geuns R, Sideris G, van Royen N, El Mahmoud R, Diletti R, Sollier C, Garot J, Van Der Hoeven N, Cortese B, Ding L, Lechthaler I, Deliargyris E, Anthopoulos P, Drouet L

August 4, 2017 | 10.4244/EIJ-D-17-00307

Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials

Geisler T, Müller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, Bernstein D, Lincoff A, Mehran R, Dangas G, Stone G

May 20, 2014 | 10.4244/EIJV10I1A16

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study

Hamon M, Rao S, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E

August 24, 2012 | 10.4244/EIJV8I4A76

1

Latest news

TAVI dysfunction, coronary sinus narrowing, carotid interventions through the snuffbox, and more

CT image showing a case of valve thrombosis after ViV TAVI

February 20, 2020

Will Your Heart Team EXCEL?

February 20, 2020

This Weeks JAA's: SAFE-A study, Coronary access after TAVR-in-TAVR and much more

February 25, 2020

New Update: CULPRIT, NOBEL, IVUS-XPL, SAFARI-STEMI

(supported by Biotronik)

February 14, 2020

Guidance Papers

Guidelines, consensus & position papers

New ahead of print: Validation of ARC-HBR criteria

February 18, 2020

New Editor-in-Chief editorial: Moving forward

Davide Capodanno

February 7, 2020

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke